Short Interest in Vaccinex, Inc. (NASDAQ:VCNX) Drops By 31.7%

Vaccinex, Inc. (NASDAQ:VCNX) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 34,500 shares, a decrease of 31.7% from the September 30th total of 50,500 shares. Currently, 2.5% of the company’s shares are short sold. Based on an average trading volume of 106,300 shares, the days-to-cover ratio is currently 0.3 days.

Vaccinex Price Performance

Vaccinex stock traded up $0.28 during trading hours on Monday, hitting $3.66. The company had a trading volume of 112,480 shares, compared to its average volume of 49,617. The firm’s fifty day moving average is $4.11 and its 200-day moving average is $5.35. Vaccinex has a fifty-two week low of $1.39 and a fifty-two week high of $13.45. The firm has a market capitalization of $6.33 million, a P/E ratio of -0.06 and a beta of 0.96.

Vaccinex (NASDAQ:VCNX) last posted its earnings results on Wednesday, August 14th. The company reported ($3.10) EPS for the quarter. The business had revenue of $0.23 million for the quarter.

Insider Activity at Vaccinex

In other Vaccinex news, Director Albert Friedberg bought 200,000 shares of Vaccinex stock in a transaction dated Wednesday, July 31st. The stock was bought at an average price of $6.15 per share, for a total transaction of $1,230,000.00. Following the completion of the acquisition, the director now directly owns 762,415 shares of the company’s stock, valued at approximately $4,688,852.25. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders bought 203,753 shares of company stock worth $1,247,255. 51.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vaccinex stock. AIGH Capital Management LLC boosted its stake in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,958 shares of the company’s stock after purchasing an additional 50,593 shares during the quarter. AIGH Capital Management LLC owned 6.90% of Vaccinex worth $707,000 at the end of the most recent quarter. 50.11% of the stock is currently owned by institutional investors and hedge funds.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.